Tag:
Diabetes
Latest Headlines
Latest Headlines
Big-name pharmas peer at Amylin's books to prep for bids
The world's biggest drugmakers have lined up to take a look at Amylin's books as the U.S.-based company prepares to entertain a first round of bids.
Docs riled by FDA's proposal to open up drug access
The FDA would free up some treatments for chronic conditions, such as asthma and diabetes, so patients could obtain them without a prescription.
UPDATED: Novo Nordisk hiring R&D, other workers in U.S. recruitment blitz
Novo Nordisk says it plans to boost its U.S. workforce almost 15% this year amid growth in the Danish drugmaker's diabetes business.
Takeda rebuffed (again) in long quest for FDA drug OK
Four months before Japan's Takeda will get hit with generic competition for the diabetes blockbuster Actos, the FDA has once again rebuffed the company's application to sell the experimental drug alogliptin.
Buzz: Amylin brings in the bankers to spur an auction
Amylin has never confirmed or denied the much repeated story that it rejected a $22 per share bid for the company by Bristol-Myers Squibb.
Victoza gets superior-to-Januvia data added to label
The change comes after a study showed Novo's drug outperformed Merck's at controlling blood sugar and helping patients lose weight.
Bristol stays in hunt for Amylin
After Amylin reportedly declined BMS' recent buyout offer, Bristol isn't giving up on its plans to gobble up the diabetes drugmaker, The Wall Street Journal reported.
UPDATED: EMA OKs Byetta for expanded treatment
The European Medicines Agency has approved an expanded use of Byetta for type 2 diabetes patients.
Lilly to focus on diabetes, cancer in China
Eli Lilly has a plan to maintain sales growth, and it involves China, a big prize drugmakers having been eyeing over the last several years.
Ampio Pharma shares soar after upbeat update on eye drug
Ampio Pharmaceuticals has rallied this morning after word about its positive interim analysis from a mid-stage study of its eye treatment sent its shares upward. With the upbeat interim analysis of the trial, the company plans to head to the FDA early to hammer out the design of a Phase III study of the drug for treating a leading cause of vision loss in diabetics.
